Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2011

View Archived Issues

Novel orexin receptor antagonists described by Merck & Co.

New free fatty acid FFA1 receptor agonists disclosed

Phase IIa study shows no appreciable difference between SYN-118 and placebo in Parkinson's disease

Genasense does not improve survival of dacarbazine-treated patients with melanoma in phase III trial

SLC23A1 gene SNP correlates with neovascular age-related macular degeneration

AZD-3199 has long-lasting bronchoprotective activity in vivo

Scientists identify alpha-1-antitrypsin as marker of cutaneous squamous cell carcinoma progression

Gene therapy JVS-100 is safe in patients with heart failure after myocardial infarction

Pfizer designs new sodium/glucose cotransporter 2 inhibitors

Anavex advances Alzheimer's disease candidate ANAVEX 2-73 to higher dose in phase I trial

Lilly forms new critical care company BioCritica

Mutations in CACNA2D1 gene may confer susceptibility to Brugada syndrome

Provectus Pharmaceuticals completes accrual in phase IIc PH-10 trial in psoriasis

Ampio Pharmaceuticals completes evaluation of phase III data on Zertane

Merck & Co. presents new NO-linked cicletanine and derivatives

NovaBay's NVC-422 shows promise in patients with epidemic keratoconjunctivitis

Novel erythropoietin production enhancers presented by Daiichi Sankyo

Prometheus to be acquired by Nestle Health Science

Preclinical study of Proteonomix's UMK-121 suggests ability to mobilize stromal stem cells

Toxicology studies completed for Alzheimer's disease drug candidate SUVN-502

FDA sets PDUFA date for fentanyl sublingual spray NDA review

FDA advisory committee to discuss Regeneron's BLA for VEGF Trap-Eye in June

Basilea Pharmaceutica reports topline data from first phase I trial of BAL-30072

Eisai and University College London to conduct joint research in neurodegenerative disease

CHMP issues negative trend vote on Bronchitol for cystic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...